Independent medication information Not a pharmacy · Not a substitute for medical advice
Psychedelics / Research compound

4-AcO-DMT

Identity, uses and research, side effects, dosage context, pricing and online access.

Research compoundPsychedelics
Reference name4-AcO-DMT
Entry typeResearch compound
CategoryPsychedelics
Chemical name4-Acetoxy-N,N-dimethyltryptamine
Other namePsilacetin
Study typeLaboratory metabolism research

DrugRX editorial reference · Sources consulted · Not independently medically reviewed

4-AcO-DMT sample, as identified by the photographer.

4-AcO-DMT sample, as identified by the photographer.

DMTrott · CC BY-SA 4.0

About 4-AcO-DMT

4-AcO-DMT, also called psilacetin or O-acetylpsilocin, is a synthetic tryptamine. It is different from psilocybin, N,N-DMT and 5-MeO-DMT.

Also searched as: 4aco dmt · 4 aco dmt · Psilacetin · O-acetylpsilocin

PRICE, COST & AVAILABILITY

Buy 4-AcO-DMT: pricing & legal access

4-AcO-DMT online: availability & product information

A “research chemical” label is not approval for human consumption or proof of legality. DrugRX has not established a lawful consumer medicine supply or verified pharmacy price. Legal treatment may depend on analogue laws and jurisdiction.

Pricing status: No live price feed or verified quote. DrugRX does not sell or dispense products.

Sources: DEA — Controlled-substance analogue guidance and statutory references

DETAILED REFERENCE

4-AcO-DMT information

What research establishes

Laboratory work has examined its metabolism using human liver microsomes. That model helps identify possible metabolites but does not establish a medicine’s effectiveness, a clinical dose or long-term safety in people.

Sources: Laboratory study of psilacetin metabolism (2022)

Risks and unknown ingredients

CDC investigated severe illnesses involving mushroom-branded products, some of which contained psychoactive substances including 4-AcO-DMT. Products could contain multiple ingredients, so the investigation does not establish that this compound alone caused every outcome.

Sources: CDC — Mushroom-product poisoning investigation (2026)

Dosage and evidence gaps

DrugRX does not provide a recreational or self-treatment dose. The cited metabolism experiment is not a human dosing study, and a package’s “microdose” claim does not resolve composition or safety uncertainty.

Sources: Laboratory study of psilacetin metabolism (2022) · CDC — Mushroom-product poisoning investigation (2026)

Interactions and clinical uncertainty

The sources cited here do not provide a validated consumer interaction table. Do not assume that interactions, contraindications or safety findings for psilocybin transfer unchanged to psilacetin.

Sources: Laboratory study of psilacetin metabolism (2022)

Psilacetin and psilocin

4-AcO-DMT is an acetylated psilocin-related compound. Psilocybin, psilocin and psilacetin have different structures; a proposed metabolic relationship does not mean that the original substances are identical.

Sources: Laboratory study of psilacetin metabolism (2022)

What the metabolism experiment measured

The cited experiment used pooled human liver microsomes and mass spectrometry to investigate possible metabolites. This is an in-vitro model, not a randomized treatment trial in patients. Laboratory metabolism findings answer a narrower question than clinical safety.

Sources: Laboratory study of psilacetin metabolism (2022)

Mushroom branding and product identity

A mushroom-branded chocolate or gummy may contain ingredients that do not match a customer’s expectation. CDC’s poisoning investigation involved products with potentially multiple psychoactive ingredients. Packaging language cannot attribute an effect to one molecule.

Sources: CDC — Mushroom-product poisoning investigation (2026)

4-AcO-DMT versus mushroom material

An isolated synthetic chemical and a mushroom specimen are different materials. The specimen can contain variable amounts of several compounds; an unverified powder can also have uncertain identity. Neither label establishes a controlled clinical preparation.

Sources: Laboratory study of psilacetin metabolism (2022) · Controlled study of 14 P. cubensis strains (2026)

Sources and editorial notes

Prepared by DrugRX using the references linked below. Sources were consulted on 2026-10-31. This page has not been independently reviewed by a clinician. Research findings, medication approval and legal permission are separate questions.

  1. Laboratory study of psilacetin metabolism (2022)
  2. CDC — Mushroom-product poisoning investigation (2026)
  3. Controlled study of 14 P. cubensis strains (2026)
  4. DEA — Controlled-substance analogue guidance and statutory references

Legal information is a dated U.S. reference. Product rules and local laws may change. Where the evidence does not establish a dose, interaction profile or price, the page states that limitation.